Aktiesnakken — Juni 2011
-
fabrikken er en eklatant fejl, sandt
-
jeg synes man må sondre mellem: at bunden er gået ud af aktiemarkedet for biotekinvesteringer og så selve det arbejde der er med at bringe
-
stoffer på markedet. På det felt rager Genmab temmeligt højt op i regnskabet
-
jeg tror faktisk ingen andre selskaber har kunnet præstere Genmabs track record på den sidste del af sondringen
-
hvis du kigger på indekset over biotek OMX, så vil du se at ALT biotek er ramt
-
lige fra LCP, Zealand Pharma til Genmab
-
Bava, Neuro, Topo, Affitech
-
you name it - its hammered
-
new york pliiing
-
ja det tror jeg
-
we´re still here

Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind